Cipla Limited

NSEI:CIPLA Stock Report

Market Cap: ₹1.2t

Cipla Future Growth

Future criteria checks 1/6

Cipla is forecast to grow earnings and revenue by 13.8% and 10.3% per annum respectively. EPS is expected to grow by 13.8% per annum. Return on equity is forecast to be 13.2% in 3 years.

Key information

13.8%

Earnings growth rate

13.79%

EPS growth rate

Pharmaceuticals earnings growth16.1%
Revenue growth rate10.3%
Future return on equity13.20%
Analyst coverage

Good

Last updated09 Jul 2026

Recent future growth updates

Analysis Article • May 16

Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next

Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Analysis Article • Jan 28

Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...
Analysis Article • Nov 02

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...

Recent updates

Narrative Update • Jun 22

CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve

Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.
Narrative Update • Jun 05

CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape

Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.
Analysis Article • May 16

Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next

Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Narrative Update • Apr 27

CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook

Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.
Narrative Update • Apr 12

CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook

Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).
Narrative Update • Mar 27

CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook

Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).
Narrative Update • Mar 13

CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook

Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).
Narrative Update • Feb 27

CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook

Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).
Narrative Update • Feb 13

CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations

Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).
Narrative Update • Jan 30

CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential

Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).
Analysis Article • Jan 28

Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...
Analysis Article • Jan 17

The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...
Narrative Update • Jan 16

CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential

Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Analysis Article • Dec 29

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 20

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Nov 02

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...
Analysis Article • Sep 24

Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...
Analysis Article • Sep 06

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Narrative Update • Sep 04

Emerging Markets And Chronic Therapies Will Open New Horizons

With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.
Analysis Article • Jul 13

Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
User avatar
New Narrative • Nov 10

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.

Earnings and Revenue Growth Forecasts

NSEI:CIPLA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2029378,69657,74137,52455,90114
3/31/2028346,68351,55236,17150,00335
3/31/2027310,68242,00730,11144,01435
3/31/2026278,27838,7929,04839,400N/A
12/31/2025279,67245,464N/AN/AN/A
9/30/2025279,65854,41127,54442,949N/A
6/30/2025274,79653,925N/AN/AN/A
3/31/2025272,67452,72534,65350,050N/A
12/31/2024267,20149,897N/AN/AN/A
9/30/2024262,64244,75129,52045,008N/A
6/30/2024258,92243,035N/AN/AN/A
3/31/2024255,36741,21627,84641,339N/A
12/31/2023251,16337,082N/AN/AN/A
9/30/2023243,40734,53225,98837,924N/A
6/30/2023235,10831,112N/AN/AN/A
3/31/2023225,59328,01920,73632,377N/A
12/31/2022222,18726,383N/AN/AN/A
9/30/2022218,87425,66020,12029,160N/A
6/30/2022216,10524,884N/AN/AN/A
3/31/2022217,07825,16826,28533,259N/A
12/31/2021210,71825,681N/AN/AN/A
9/30/2021207,61625,87628,36237,113N/A
6/30/2021202,80125,417N/AN/AN/A
3/31/2021191,20524,04929,41837,552N/A
12/31/2020188,77922,374N/AN/AN/A
9/30/2020180,80218,40323,62731,968N/A
6/30/2020174,37716,462N/AN/AN/A
3/31/2020170,80515,46520,68430,685N/A
12/31/2019171,20616,678N/AN/AN/A
9/30/2019167,57216,489N/A25,720N/A
6/30/2019163,73315,546N/AN/AN/A
3/31/2019163,23215,277N/A16,911N/A
12/31/2018155,22413,391N/AN/AN/A
9/30/2018154,28714,074N/AN/AN/A
6/30/2018154,99214,530N/AN/AN/A
3/31/2018151,05314,105N/A14,628N/A
12/31/2017147,61811,701N/AN/AN/A
9/30/2017144,95111,444N/AN/AN/A
6/30/2017141,63710,762N/AN/AN/A
3/31/2017143,34010,064N/A23,818N/A
12/31/2016142,50911,213N/AN/AN/A
9/30/2016137,54710,071N/AN/AN/A
6/30/2016134,33512,219N/AN/AN/A
3/31/2016135,48013,600N/A17,408N/A
12/31/2015135,04416,847N/AN/AN/A
9/30/2015131,63316,694N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CIPLA's forecast earnings growth (13.8% per year) is above the savings rate (6.9%).

Earnings vs Market: CIPLA's earnings (13.8% per year) are forecast to grow slower than the Indian market (16.2% per year).

High Growth Earnings: CIPLA's earnings are forecast to grow, but not significantly.

Revenue vs Market: CIPLA's revenue (10.3% per year) is forecast to grow slower than the Indian market (11% per year).

High Growth Revenue: CIPLA's revenue (10.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CIPLA's Return on Equity is forecast to be low in 3 years time (13.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 16:58
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cipla Limited is covered by 55 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited